SDSubhash Dhawan

Subhash Dhawan

*This is an algorithmically generated author record based on publicly available information.

Subhash Dhawan has a total of 8 co-authors. Here are the top co-authors by number of shared publications:

  • Alena Dabrazhynetskaya

    Center for Biologics Evaluation and Research, Food and Drug Administration Silver Spring MD USA

    1 shared publication
  • Hanxia Huang

    Center for Biologics Evaluation and Research, Food and Drug Administration Silver Spring MD USA

    1 shared publication
  • Jacob A. Pluznik

    Affiliation Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia, United States of America

    1 shared publication
  • Jiwen Zheng

    Office of Science and Engineering Laboratories Center for Devices and Radiological Health, Food and Drug Administration Silver Spring MD USA

    1 shared publication
  • Kenneth M. Yamada

    National Institute of Dental and Craniofacial Research National Institutes of Health Bethesda MD USA

    1 shared publication
  • Paul W. Buehler

    Center for Biologics Evaluation and Research, Food and Drug Administration Silver Spring MD USA

    1 shared publication

Latest Publications

  • Open Access

    Therapeutic Potential of Inducible Endogenous Cytoprotective Heme Oxygenase-1 in Mitigating SARS-CoV-2 Infection and Associated Inflammation

    by Subhash Dhawan

    The inducible cytoprotective enzyme heme oxygenase-1 (HO-1) has gained significant recognition in recent years for mediating strong cellular resistance to a broad range of viral infections, regardless of the type of viruses, viral strains, or mutants. HO-1 is not a typical antiviral agent that targets any particular pathogen. It is a “viral tropism independent” endogenous host defense factor that upon induction provides general cellular protection against pathogens. By virtue of HO-1 being widely distributed intracellular enzyme in virtually every cell, this unique host factor presents a novel class of generic host defense system against a variety of viral infections. This Viewpoint proposes pharmacological evaluation of the HO-1-dependent cellular resistance for its potential in mitigating infections by deadly viruses, including the current severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), its variants, and mutants. HO-1-dependent cellular resistance against SARS-CoV-2 can complement current medical modalities for much effective control of the COVID-19 pandemic, especially with constantly emerging new viral variants and limited therapeutic options to treat SARS-CoV-2 infection and associated severe health consequences.


  • Open Access

    Hemin activation abrogates Mycoplasma hyorhinis replication in chronically infected prostate cancer cells via heme oxygenase‐1 induction

    by Hanxia Huang, Alena Dabrazhynetskaya, Jacob Pluznik, Jiwen Zheng, Yong Wu, Vladimir Chizhikov, Paul W. Buehler, Kenneth M. Yamada, Subhash Dhawan

    Mycoplasma hyorhinis (M. hyorhinis) lacks a cell wall and resists multiple antibiotics. We describe here the striking >90% inhibitory effect of hemin, a natural inducer of the cytoprotective enzyme heme oxygenase-1 (HO-1), on M. hyorhinis replication in chronically infected LNCaP prostate cancer cells. The role of HO-1 in interrupting M. hyorhinis replication was confirmed by HO-1-specific siRNA suppression of hemin-induced HO-1 protein expression, which increased intracellular M. hyorhinis DNA levels in LNCaP cells. Proteomic analysis and transmission electron microscopy of hemin-treated cells confirmed the complete absence of M. hyorhinis proteins and intact microorganisms, respectively, strongly supporting these findings. Our study is the first to our knowledge suggesting therapeutic potential for activated HO-1 in cellular innate responses against mycoplasma infection.